Fields do not abandon a compound that works
They are not intended for human, veterinary, or therapeutic use
FIGURE 3 Secondary outcomes Similarly, the risk of all-cause mortality alone was lower in the tirzepatide group, with 45 events (incidence rate: 1.0 per 100 person-years) compared to 119 events (incidence rate: 1.9 per 100 person-years) in the control group (HR, 0.52
However, as the initial "honeymoon phase" wears off, many users are encountering two significant hurdles: the dreaded weight-loss plateau and a decline in overall quality of life (fatigue, muscle loss, and GI distress)
The observation that BPC-157 appears to activate this pathway (via phosphorylation of FAK and paxillin) in cultured fibroblasts provides a direct molecular explanation for how it might accelerate wound closure and tissue repair in research models